Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction

Zhong Li, Matthew Brecher, Yong Qiang Deng, Jing Zhang, Srilatha Sakamuru, Binbin Liu, Ruili Huang, Cheri A. Koetzner, Christina A. Allen, Susan A. Jones, Haiying Chen, Na Na Zhang, Min Tian, Fengshan Gao, Qishan Lin, Nilesh Banavali, Jia Zhou, Nathan Boles, Menghang Xia, Laura D. KramerCheng Feng Qin, Hongmin Li

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Recent outbreaks of Zika virus (ZIKV) highlight an urgent need for therapeutics. The protease complex NS2BNS3 plays essential roles during flaviviral polyprotein processing, and thus represents an attractive drug target. Here, we developed a split luciferase complementation-based high-throughput screening assay to identify orthosteric inhibitors that directly target flavivirus NS2B-NS3 interactions. By screening a total of 2 816 approved and investigational drugs, we identified three potent candidates, temoporfin, niclosamide, and nitazoxanide, as flavivirus NS2BNS3 interaction inhibitors with nanomolar potencies. Significantly, the most potent compound, temoporfin, not only inhibited ZIKV replication in human placental and neural progenitor cells, but also prevented ZIKV-induced viremia and mortality in mouse models. Structural docking suggests that temoporfin potentially binds NS3 pockets that hold critical NS2B residues, thus inhibiting flaviviral polyprotein processing in a non-competitive manner. As these drugs have already been approved for clinical use in other indications either in the USA or other countries, they represent promising and easily developed therapies for the management of infections by ZIKV and other flaviviruses.

Original languageEnglish (US)
Pages (from-to)1046-1064
Number of pages19
JournalCell Research
Volume27
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Flavivirus
Polyproteins
nitazoxanide
Niclosamide
Pharmaceutical Preparations
Investigational Drugs
High-Throughput Screening Assays
Viremia
Virus Replication
Luciferases
Disease Outbreaks
Peptide Hydrolases
Stem Cells
Mortality
Therapeutics
Zika Virus
temoporfin

Keywords

  • Inhibitor
  • NS2B-NS3
  • Protease
  • Zika virus

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Li, Z., Brecher, M., Deng, Y. Q., Zhang, J., Sakamuru, S., Liu, B., ... Li, H. (2017). Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. Cell Research, 27(8), 1046-1064. https://doi.org/10.1038/cr.2017.88

Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. / Li, Zhong; Brecher, Matthew; Deng, Yong Qiang; Zhang, Jing; Sakamuru, Srilatha; Liu, Binbin; Huang, Ruili; Koetzner, Cheri A.; Allen, Christina A.; Jones, Susan A.; Chen, Haiying; Zhang, Na Na; Tian, Min; Gao, Fengshan; Lin, Qishan; Banavali, Nilesh; Zhou, Jia; Boles, Nathan; Xia, Menghang; Kramer, Laura D.; Qin, Cheng Feng; Li, Hongmin.

In: Cell Research, Vol. 27, No. 8, 01.08.2017, p. 1046-1064.

Research output: Contribution to journalArticle

Li, Z, Brecher, M, Deng, YQ, Zhang, J, Sakamuru, S, Liu, B, Huang, R, Koetzner, CA, Allen, CA, Jones, SA, Chen, H, Zhang, NN, Tian, M, Gao, F, Lin, Q, Banavali, N, Zhou, J, Boles, N, Xia, M, Kramer, LD, Qin, CF & Li, H 2017, 'Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction', Cell Research, vol. 27, no. 8, pp. 1046-1064. https://doi.org/10.1038/cr.2017.88
Li, Zhong ; Brecher, Matthew ; Deng, Yong Qiang ; Zhang, Jing ; Sakamuru, Srilatha ; Liu, Binbin ; Huang, Ruili ; Koetzner, Cheri A. ; Allen, Christina A. ; Jones, Susan A. ; Chen, Haiying ; Zhang, Na Na ; Tian, Min ; Gao, Fengshan ; Lin, Qishan ; Banavali, Nilesh ; Zhou, Jia ; Boles, Nathan ; Xia, Menghang ; Kramer, Laura D. ; Qin, Cheng Feng ; Li, Hongmin. / Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction. In: Cell Research. 2017 ; Vol. 27, No. 8. pp. 1046-1064.
@article{edbde66bdae64d6493f210a2cc0d25c7,
title = "Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction",
abstract = "Recent outbreaks of Zika virus (ZIKV) highlight an urgent need for therapeutics. The protease complex NS2BNS3 plays essential roles during flaviviral polyprotein processing, and thus represents an attractive drug target. Here, we developed a split luciferase complementation-based high-throughput screening assay to identify orthosteric inhibitors that directly target flavivirus NS2B-NS3 interactions. By screening a total of 2 816 approved and investigational drugs, we identified three potent candidates, temoporfin, niclosamide, and nitazoxanide, as flavivirus NS2BNS3 interaction inhibitors with nanomolar potencies. Significantly, the most potent compound, temoporfin, not only inhibited ZIKV replication in human placental and neural progenitor cells, but also prevented ZIKV-induced viremia and mortality in mouse models. Structural docking suggests that temoporfin potentially binds NS3 pockets that hold critical NS2B residues, thus inhibiting flaviviral polyprotein processing in a non-competitive manner. As these drugs have already been approved for clinical use in other indications either in the USA or other countries, they represent promising and easily developed therapies for the management of infections by ZIKV and other flaviviruses.",
keywords = "Inhibitor, NS2B-NS3, Protease, Zika virus",
author = "Zhong Li and Matthew Brecher and Deng, {Yong Qiang} and Jing Zhang and Srilatha Sakamuru and Binbin Liu and Ruili Huang and Koetzner, {Cheri A.} and Allen, {Christina A.} and Jones, {Susan A.} and Haiying Chen and Zhang, {Na Na} and Min Tian and Fengshan Gao and Qishan Lin and Nilesh Banavali and Jia Zhou and Nathan Boles and Menghang Xia and Kramer, {Laura D.} and Qin, {Cheng Feng} and Hongmin Li",
year = "2017",
month = "8",
day = "1",
doi = "10.1038/cr.2017.88",
language = "English (US)",
volume = "27",
pages = "1046--1064",
journal = "Cell Research",
issn = "1001-0602",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Existing drugs as broad-spectrum and potent inhibitors for Zika virus by targeting NS2B-NS3 interaction

AU - Li, Zhong

AU - Brecher, Matthew

AU - Deng, Yong Qiang

AU - Zhang, Jing

AU - Sakamuru, Srilatha

AU - Liu, Binbin

AU - Huang, Ruili

AU - Koetzner, Cheri A.

AU - Allen, Christina A.

AU - Jones, Susan A.

AU - Chen, Haiying

AU - Zhang, Na Na

AU - Tian, Min

AU - Gao, Fengshan

AU - Lin, Qishan

AU - Banavali, Nilesh

AU - Zhou, Jia

AU - Boles, Nathan

AU - Xia, Menghang

AU - Kramer, Laura D.

AU - Qin, Cheng Feng

AU - Li, Hongmin

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Recent outbreaks of Zika virus (ZIKV) highlight an urgent need for therapeutics. The protease complex NS2BNS3 plays essential roles during flaviviral polyprotein processing, and thus represents an attractive drug target. Here, we developed a split luciferase complementation-based high-throughput screening assay to identify orthosteric inhibitors that directly target flavivirus NS2B-NS3 interactions. By screening a total of 2 816 approved and investigational drugs, we identified three potent candidates, temoporfin, niclosamide, and nitazoxanide, as flavivirus NS2BNS3 interaction inhibitors with nanomolar potencies. Significantly, the most potent compound, temoporfin, not only inhibited ZIKV replication in human placental and neural progenitor cells, but also prevented ZIKV-induced viremia and mortality in mouse models. Structural docking suggests that temoporfin potentially binds NS3 pockets that hold critical NS2B residues, thus inhibiting flaviviral polyprotein processing in a non-competitive manner. As these drugs have already been approved for clinical use in other indications either in the USA or other countries, they represent promising and easily developed therapies for the management of infections by ZIKV and other flaviviruses.

AB - Recent outbreaks of Zika virus (ZIKV) highlight an urgent need for therapeutics. The protease complex NS2BNS3 plays essential roles during flaviviral polyprotein processing, and thus represents an attractive drug target. Here, we developed a split luciferase complementation-based high-throughput screening assay to identify orthosteric inhibitors that directly target flavivirus NS2B-NS3 interactions. By screening a total of 2 816 approved and investigational drugs, we identified three potent candidates, temoporfin, niclosamide, and nitazoxanide, as flavivirus NS2BNS3 interaction inhibitors with nanomolar potencies. Significantly, the most potent compound, temoporfin, not only inhibited ZIKV replication in human placental and neural progenitor cells, but also prevented ZIKV-induced viremia and mortality in mouse models. Structural docking suggests that temoporfin potentially binds NS3 pockets that hold critical NS2B residues, thus inhibiting flaviviral polyprotein processing in a non-competitive manner. As these drugs have already been approved for clinical use in other indications either in the USA or other countries, they represent promising and easily developed therapies for the management of infections by ZIKV and other flaviviruses.

KW - Inhibitor

KW - NS2B-NS3

KW - Protease

KW - Zika virus

UR - http://www.scopus.com/inward/record.url?scp=85026675178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026675178&partnerID=8YFLogxK

U2 - 10.1038/cr.2017.88

DO - 10.1038/cr.2017.88

M3 - Article

C2 - 28685770

AN - SCOPUS:85026675178

VL - 27

SP - 1046

EP - 1064

JO - Cell Research

JF - Cell Research

SN - 1001-0602

IS - 8

ER -